Hibiscus sabdariffa linnaeus aqueous extracts attenuate the progression of renal injury in 5/6 nephrectomy rats

Renal Failure

Volumn 35, Issue 1, 2013, Pages 118-125

  Seujange, Yuyen ^a   Leelahavanichkul, Asada ^b   Yisarakun, Waranurin ^a   Khawsuk, Witoon ^a   Meepool, Ardool ^a   Phamonleatmongkol, Ponlapat ^a   Saechau, Walai ^a   Onlamul, Winita ^a   Tantiwarattanatikul, Pansa ^a   Oonsook, Worapong ^a   Eiam Ong, Somchit ^b  

^a BURAPHA UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

5 6 nephrectomy; Chronic kidney disease; Hibiscus sabdariffa Linn.; Malondialdehyde; Systolic blood pressure

Indexed keywords

CREATININE; HIBISCUS SABDARIFFA EXTRACT; MALONALDEHYDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE COURSE; HIBISCUS SABDARIFFA; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; VASODILATATION;

ACUTE KIDNEY INJURY; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HIBISCUS; MALE; NEPHRECTOMY; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84872476031     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.741468     Document Type: Article

References (34)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
2. Patel SS, Kimmel PL, Singh A. New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI. Semin Nephrol. 2002;22:449-458. (Pubitemid 35355717)
3. Mitka M. Report notes increase in kidney disease. JAM.A.. 2008;300:2473-2474.
4. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12. (Pubitemid 36043346)
5. Herrera-Arellano A, Flores-Romero S, Chavez-Soto M.A., Tortoriello J. Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial. Phytomedicine. 2004;11:375-382. (Pubitemid 38980517)
6. Wang CJ, Wang JM, Lin WL, Chu CY, Chou FP, Tseng TH. Protective effect of Hibiscus anthocyanins against tert-butyl hydroperoxide-induced hepatic toxicity in rats. Food Chem Toxicol. 2000;38:411-416.
7. Gowali FM. Hibiscin for mucin. Stain Technol. 1982;57:57-58. (Pubitemid 12083014)
8. Hirunpanich V, Utaipat A, Morales NP, et al. Hypocholesterolemic and antioxidant effects of aqueous extracts from the dried calyx of Hibiscus sabdariffa L. in hypercholesterolemic rats. J EthnopharM.A.col. 2006;103:252-260. (Pubitemid 41796926)
9. Hirunpanich V, Utaipat A, Morales NP, et al. Antioxidant effects of aqueous extracts from dried calyx of Hibiscus sabdariffa Linn. (Roselle) in vitro using rat low-density lipoprotein (LDL). Biol Pharm Bull. 2005;28:481-484. (Pubitemid 40879972)
10. Mojiminiyi FB, Dikko M, MuhamM.A.d BY, et al. Antihypertensive effect of an aqueous extract of the calyx of Hibiscus sabdariffa. Fitoterapia. 2007;78:292-297. (Pubitemid 46777204)
11. Odigie IP, Ettarh RR, Adigun SA. Chronic administration of aqueous extract of Hibiscus sabdariffa attenuates hypertension and reverses cardiac hypertrophy in 2K-1C hypertensive rats. J EthnopharM.A.col. 2003;86:181-185. (Pubitemid 36542874)
12. Adegunloye BJ, Omoniyi JO, Owolabi OA, Ajagbonna OP, Sofola OA, Coker HA. Mechanisms of the blood pressure lowering effect of the calyx extract of Hibiscus sabdariffa in rats. Afr J Med Med Sci. 1996;25:235-238.
13. Sarr M, Ngom S, Kane MO, et al. In vitro vasorelaxation mechanisms of bioactive compounds extracted from Hibiscus sabdariffa on rat thoracic aorta. Nutr Metab (Lond). 2009;6:45.
14. Jonadet M, Bastide J, Bastide P, Boyer B, Carnat AP, LaM.A.ison JL. [In vitro enzyme inhibitory and in vivo cardioprotective activities of hibiscus (Hibiscus sabdariffa L.)]. J Pharm Belg. 1990;45:120-124. (Pubitemid 20156176)
15. Lee WC, Wang CJ, Chen YH, et al. Polyphenol extracts from Hibiscus sabdariffa Linnaeus attenuate nephropathy in experimental type 1 diabetes. J Agric Food Chem. 2009;57: 2206-2210.
16. Griffin KA, Picken M, Bidani AK. Method of renal M.A.ss reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol. 1994;4:2023-2031. (Pubitemid 24977009)
17. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in aniM.A.l tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-358. (Pubitemid 9194347)
18. Leelahavanichkul A, Yan Q, Hu X, et al. Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney Int. 2010;78:1136-1153.
19. M.A.cKay K, Striker LJ, Pinkert CA, Brinster RL, Striker GE. Glomerulosclerosis and renal cysts in mice transgenic for the early region of SV40. Kidney Int. 1987;32:827-837. (Pubitemid 18015513)
20. Farmer EE, Davoine C. Reactive electrophile species. Curr Opin Plant Biol. 2007;10:380-386. (Pubitemid 47126951)
21. Inagi R,Miyata T. Oxidative protein daM.A.ge with carbohydrates and lipids in uremia: 'carbonyl stress'. Blood Purif. 1999;17:95-98. (Pubitemid 29403566)
22. Siems W, Quast S, Carluccio F, et al. Oxidative stress in chronic renal failure as a cardiovascular risk factor. Clin Nephrol. 2002;58 (Suppl 1):S12-S19.
23. Kadowaki D, Anraku M, Tasaki Y, et al. Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats. Biol Pharm Bull. 2009;32:2041-2045.
24. Vaziri ND, Oveisi F, Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int. 1998;53:1748-1754. (Pubitemid 28243760)
25. Paul JL, M.A.n NK, Moatti N, Raichvarg D. [Membrane phospholipid peroxidation in renal insufficiency and chronic hemodialysis]. Nephrologie. 1991;12:4-7.
26. Trznadel K, Pawlicki L, Kedziora J, Luciak M, Blaszczyk J, Buczynski A. Superoxide anion generation, erythrocytes superoxide dismutase activity, and lipid peroxidation during hemoperfusion and hemodialysis in chronic uremic patients. Free Radic Biol Med. 1989;6:393-397. (Pubitemid 19096931)
27. Durak I, Akyol O, Basesme E, Canbolat O, Kavutcu M. Reduced erythrocyte defense mechanisms against free radical toxicity in patients with chronic renal failure. Nephron. 1994;66:76-80. (Pubitemid 23355581)
28. Turi S, Nemeth I, Vargha I, M.A.tkovics B, Dobos E. Erythrocyte defense mechanisms against free oxygen radicals in hemodialyzed uremic children. Pediatr Nephrol. 1991;5:179-183.
29. Seca AM, Silva AM, Silvestre AJ, Cavaleiro JA, Domingues FM, Pascoal-Neto C. Phenolic constituents from the core of kenaf (Hibiscus cannabinus). Phytochemistry. 2001;56:759-767. (Pubitemid 32267736)
30. Shirwaikar A,M.A.lini S, KuM.A.ri SC. Protective effect of Pongamia pinnata flowers against cisplatin and gentamicin induced nephrotoxicity in rats. Indian J Exp Biol. 2003;41:58-62. (Pubitemid 36052889)
31. Fleet M, OsM.A.n F, KoM.A.ragiri R, Fritz A. Protein catabolism in advanced renal disease: role of cytokines. Clin Nephrol. 2008;70:91-100.
32. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between M.A.lnutrition, inflamM.A.tion, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899-1911. (Pubitemid 29197978)
33. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-Alpha: central factors in the altered cytokine network of uremia-The good, the bad, and the ugly. Kidney Int. 2005;67:1216-1233. (Pubitemid 40463099)
34. Zoccali C, M.A.llaM.A.ci F, Tripepi G. InflamM.A.tion and atherosclerosis in end-stage renal disease. Blood Purif. 2003; 21:29-36. (Pubitemid 36173345)